vs

Side-by-side financial comparison of FULTON FINANCIAL CORP (FULT) and MADRIGAL PHARMACEUTICALS, INC. (MDGL). Click either name above to swap in a different company.

FULTON FINANCIAL CORP is the larger business by last-quarter revenue ($336.2M vs $321.1M, roughly 1.0× MADRIGAL PHARMACEUTICALS, INC.). FULTON FINANCIAL CORP runs the higher net margin — 28.2% vs -18.2%, a 46.4% gap on every dollar of revenue. On growth, MADRIGAL PHARMACEUTICALS, INC. posted the faster year-over-year revenue change (210.8% vs 4.2%).

Fulton Financial Corporation is an American regional financial services holding company, headquartered in Lancaster, Pennsylvania.

Intercept Pharmaceuticals, Inc. is an American biopharmaceutical company incorporated in 2002, focusing on the development of novel synthetic bile acid analogs to treat chronic liver diseases, such as primary biliary cirrhosis (PBC) now called primary biliary cholangitis, non-alcoholic fatty liver disease, cirrhosis, portal hypertension, primary sclerosing cholangitis and also the intestinal disorder, bile acid diarrhea.

FULT vs MDGL — Head-to-Head

Bigger by revenue
FULT
FULT
1.0× larger
FULT
$336.2M
$321.1M
MDGL
Growing faster (revenue YoY)
MDGL
MDGL
+206.6% gap
MDGL
210.8%
4.2%
FULT
Higher net margin
FULT
FULT
46.4% more per $
FULT
28.2%
-18.2%
MDGL

Income Statement — Q1 FY2026 vs Q4 FY2025

Metric
FULT
FULT
MDGL
MDGL
Revenue
$336.2M
$321.1M
Net Profit
$94.8M
$-58.6M
Gross Margin
Operating Margin
-18.6%
Net Margin
28.2%
-18.2%
Revenue YoY
4.2%
210.8%
Net Profit YoY
1.9%
1.4%
EPS (diluted)
$0.55
$-2.55

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
FULT
FULT
MDGL
MDGL
Q1 26
$336.2M
Q4 25
$336.0M
$321.1M
Q3 25
$334.6M
$287.3M
Q2 25
$324.1M
$212.8M
Q1 25
$318.4M
$137.3M
Q4 24
$319.6M
$103.3M
Q3 24
$317.7M
$62.2M
Q2 24
$334.7M
Net Profit
FULT
FULT
MDGL
MDGL
Q1 26
$94.8M
Q4 25
$99.0M
$-58.6M
Q3 25
$100.5M
$-114.2M
Q2 25
$99.2M
$-42.3M
Q1 25
$93.0M
$-73.2M
Q4 24
$68.6M
$-59.4M
Q3 24
$63.2M
$-107.0M
Q2 24
$95.0M
Gross Margin
FULT
FULT
MDGL
MDGL
Q1 26
Q4 25
Q3 25
Q2 25
Q1 25
96.7%
Q4 24
Q3 24
Q2 24
Operating Margin
FULT
FULT
MDGL
MDGL
Q1 26
Q4 25
35.7%
-18.6%
Q3 25
38.2%
-39.7%
Q2 25
37.8%
-22.2%
Q1 25
36.1%
-57.8%
Q4 24
27.0%
-64.8%
Q3 24
25.1%
-187.1%
Q2 24
30.8%
Net Margin
FULT
FULT
MDGL
MDGL
Q1 26
28.2%
Q4 25
29.5%
-18.2%
Q3 25
30.0%
-39.8%
Q2 25
30.6%
-19.9%
Q1 25
29.2%
-53.4%
Q4 24
21.5%
-57.5%
Q3 24
19.9%
-172.0%
Q2 24
28.4%
EPS (diluted)
FULT
FULT
MDGL
MDGL
Q1 26
$0.55
Q4 25
$0.53
$-2.55
Q3 25
$0.53
$-5.08
Q2 25
$0.53
$-1.90
Q1 25
$0.49
$-3.32
Q4 24
$0.36
$-2.50
Q3 24
$0.33
$-4.92
Q2 24
$0.52

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
FULT
FULT
MDGL
MDGL
Cash + ST InvestmentsLiquidity on hand
$198.7M
Total DebtLower is stronger
$339.9M
Stockholders' EquityBook value
$3.5B
$602.7M
Total Assets
$32.2B
$1.3B
Debt / EquityLower = less leverage
0.56×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
FULT
FULT
MDGL
MDGL
Q1 26
Q4 25
$198.7M
Q3 25
$295.7M
Q2 25
$186.2M
Q1 25
$183.6M
Q4 24
$100.0M
Q3 24
$232.7M
Q2 24
Total Debt
FULT
FULT
MDGL
MDGL
Q1 26
Q4 25
$339.9M
Q3 25
$339.8M
Q2 25
$118.4M
Q1 25
$118.0M
Q4 24
$117.6M
Q3 24
$117.1M
Q2 24
Stockholders' Equity
FULT
FULT
MDGL
MDGL
Q1 26
$3.5B
Q4 25
$3.5B
$602.7M
Q3 25
$3.4B
$625.7M
Q2 25
$3.3B
$696.0M
Q1 25
$3.3B
$710.6M
Q4 24
$3.2B
$754.4M
Q3 24
$3.2B
$777.2M
Q2 24
$3.1B
Total Assets
FULT
FULT
MDGL
MDGL
Q1 26
$32.2B
Q4 25
$32.1B
$1.3B
Q3 25
$32.0B
$1.4B
Q2 25
$32.0B
$1.0B
Q1 25
$32.1B
$996.6M
Q4 24
$32.1B
$1.0B
Q3 24
$32.2B
$1.1B
Q2 24
$31.8B
Debt / Equity
FULT
FULT
MDGL
MDGL
Q1 26
Q4 25
0.56×
Q3 25
0.54×
Q2 25
0.17×
Q1 25
0.17×
Q4 24
0.16×
Q3 24
0.15×
Q2 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
FULT
FULT
MDGL
MDGL
Operating Cash FlowLast quarter
$-133.5M
Free Cash FlowOCF − Capex
$-133.8M
FCF MarginFCF / Revenue
-41.7%
Capex IntensityCapex / Revenue
0.1%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
FULT
FULT
MDGL
MDGL
Q1 26
Q4 25
$304.5M
$-133.5M
Q3 25
$116.1M
$79.8M
Q2 25
$91.7M
$-47.1M
Q1 25
$703.0K
$-88.9M
Q4 24
$416.6M
$-104.5M
Q3 24
$-22.0M
$-67.0M
Q2 24
$157.8M
Free Cash Flow
FULT
FULT
MDGL
MDGL
Q1 26
Q4 25
$-133.8M
Q3 25
$79.0M
Q2 25
Q1 25
Q4 24
$-104.7M
Q3 24
$-67.8M
Q2 24
FCF Margin
FULT
FULT
MDGL
MDGL
Q1 26
Q4 25
-41.7%
Q3 25
27.5%
Q2 25
Q1 25
Q4 24
-101.3%
Q3 24
-109.0%
Q2 24
Capex Intensity
FULT
FULT
MDGL
MDGL
Q1 26
Q4 25
0.1%
Q3 25
0.3%
Q2 25
0.0%
Q1 25
0.0%
Q4 24
0.2%
Q3 24
1.3%
Q2 24
Cash Conversion
FULT
FULT
MDGL
MDGL
Q1 26
Q4 25
3.08×
Q3 25
1.16×
Q2 25
0.92×
Q1 25
0.01×
Q4 24
6.07×
Q3 24
-0.35×
Q2 24
1.66×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

FULT
FULT

Segment breakdown not available.

MDGL
MDGL

Rebates Customer Fees Credits Co Pay Assistance And Other$208.5M65%
Other$76.0M24%
Chargebacks Discounts For Prompt Pay And Other Allowances$36.6M11%

Related Comparisons